|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
TYPE OF REPORT | 8. Year | 2015 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Tom DiLenge |
Date | 1/20/2016 8:42:47 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
EPA Regulations on Agricultural Biotechnology
---Pesticide Registration Improvement Act
Livestock Cloning/Product Labeling
---Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
---FDA Approval
---Labeling
---One Health Legislation (Senate Discussion Draft)
---H.R.2029: Consolidated Appropriations Act for FY 2016
-------Amendment to Restrict FDA Approval of GE Salmon
-------Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
---U.S. Government Policy
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---H.R.2029: Consolidated Appropriations Act for FY 2016
Transpacific Partnership
---Sanitary and Phytosanitary Issues
Adventitious Presence (Low Level Presence)
---International Low Level Presence Policies
Funding for the USDA
---H.R.2029: Consolidated Appropriations Act for FY 2016
Foreign Agricultural Biotechnology Laws and Regulations
---Asynchrony of International Approvals
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Korea Biotechnology Regulations
Potential Regulation of New Genetic Modification Technologies
Funding for Biomass Crop Assistance Program
---H.R.2029: Consolidated Appropriations Act for FY 2016
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Co-existence of Production Systems
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Science & Technology Policy (OSTP), U.S. Trade Representative (USTR), Office of the Vice President of the United States, Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Livestock Cloning/Product Labeling
---Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
---FDA Approval
---Labeling
---One Health Legislation (Senate Discussion Draft)
---H.R.2029: Consolidated Appropriations Act for FY 2016
-------Amendment to Restrict FDA Approval of GE Salmon
-------Amendment on GE Salmon Labeling
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Funding for the USDA
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for FDA
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for the National Institutes of Health
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biomass Crop Assistance Program
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biofuels
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biorefineries
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Erick |
Lutt |
|
|
|
Kathleen |
Holcombe |
|
|
|
Kelly |
Cappio |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Anna |
Weinstein |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Renewable Chemicals/Bio-based Products (Non-Funding)
---Nomenclature Usage
---Pre-market Notification Review
---S. 697: Chemical Safety for the 21st Century Act
---H.R. 2576: TSCA Modernization Act
---S. 1447: Sustainable Chemistry Research and Development Act
---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
Funding for Renewable Chemicals/Bio-based Products
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Charles |
Fritts |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Reform
---S.1137: The PATENTS Act of 2015
---H.R. 9: Innovation Act
---Implementation of the America Invents Act of 2011
---H.R.2029: Consolidated Appropriations Act for FY 2016
Bayh-Dole Act/Tech Transfer
---Commercialization of Federally Funded Research Initiative
Intellectual Property International Enforcement
Transpacific Partnership
---Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
Drug Patent Settlements
---S.1137: The PATENTS Act of 2015
---S. 2019: Preserve Access to Affordable Generics Act of 2015
Inter Partes Review
---Implementation of the American Invents Act of 2011
---S.1137: The PATENTS Act of 2015
---H.R. 9: Innovation Act
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Congressional Budget Office (CBO), Patent & Trademark Office (PTO), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Catharine |
Harris |
|
|
|
Charles |
Fritts |
|
|
|
Hans |
Sauer |
|
|
|
Jamie |
Gregorian |
|
|
|
Joseph |
Damond |
|
|
|
Nicolas |
Magallanes |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CSP
16. Specific lobbying issues
Livestock Cloning/Product Labeling
---Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
---FDA Approval
---Labeling
---One Health Legislation (Senate Discussion Draft)
---H.R.2029: Consolidated Appropriations Act for FY 2016
-------Amendment to Restrict FDA Approval of GE Salmon
-------Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
---U.S. Government Policy
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---H.R.2029: Consolidated Appropriations Act for FY 2016
Biosimilars
---Colombia Biologics Regulations
---Mexico Biologics Regulations
---Implementation of Affordable Care Act
---Interchangeability and Pharmacy Substitution
---Naming
USDA/APHIS Agricultural Biotechnology Regulations
---Efficient Science-Based Review of Biotech Products
---Co-existence of Production Systems
Drug Importation
---H.R.2029: Consolidated Appropriations Act for FY 2016
---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA), Office of Management & Budget (OMB), Office of the Vice President of the United States, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Anna |
Weinstein |
|
|
|
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Kathleen |
Holcombe |
|
|
|
Nicolas |
Magallanes |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation Extension
---Climate Change Benefits
---Production Tax Credit Extension
---Implementation of the Agricultural Act of 2014
---H.R. 2029: Consolidated Appropriations Act of FY 2016
-------Protecting Americans from Tax Hikes (PATH) Act of 2015
Renewable Chemicals/Bio-based Products (Non-Funding)
---Nomenclature Usage
---Pre-market Notification Review
---S. 697: Chemical Safety for the 21st Century Act
---H.R. 2576: TSCA Modernization Act
---S. 1447: Sustainable Chemistry Research and Development Act
---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
Funding for Biomass Crop Assistance Program
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biofuels
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biorefineries
--H.R.2029: Consolidated Appropriations Act for FY 2016
EPA Regulation of Biotechnology
---EPA Points to Consider Guidance Document for GE Algae
Renewable Fuel Standard
---Proposed Rule
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Dana |
OBrien |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---Accelerated Depreciation Extension
---Climate Change Benefits
---Production Tax Credit Extension
---Implementation of the Agricultural Act of 2014
---H.R. 2029: Consolidated Appropriations Act of FY 2016
-------Protecting Americans from Tax Hikes (PATH) Act of 2015
Renewable Chemicals/Bio-based Products (Non-Funding)
---Nomenclature Usage
---Pre-market Notification Review
---S. 697: Chemical Safety for the 21st Century Act
---H.R. 2576: TSCA Modernization Act
---S. 1447: Sustainable Chemistry Research and Development Act
---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
Funding for Biomass Crop Assistance Program
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Renewable Chemicals/Bio-based Products
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biofuels
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biorefineries
--H.R.2029: Consolidated Appropriations Act for FY 2016
EPA Regulation of Biotechnology
---EPA Points to Consider Guidance Document for GE Algae
Renewable Fuel Standard
---Proposed Rule
Review of the Federal Coordinated Framework for Biotechnology Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Biosimilars
---Biosimilar User Fee Act Implementation
---Coding
---Colombia Biologics Regulations
---Implementation of Affordable Care Act
---Interchangeability and Pharmacy Substitution
---Mexico Biologics Regulations
---Naming
Funding for the National Institutes of Health
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Centers for Disease Control and Prevention Vaccine Programs
---H.R.2029: Consolidated Appropriations Act for FY 2016
Vaccine Access/Financing
---Vaccine Injury Compensation Program
340B Drug Pricing Program
---Program Implementation & Oversight
---H.R.2029: Consolidated Appropriations Act for FY 2016
Medicaid Pricing and Rebates
---Implementation of Affordable Care Act
---Average Manufacturer Price Calculations
Drug Importation
---H.R.2029: Consolidated Appropriations Act for FY 2016
---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015
Diagnostics and Personalized Medicine Regulation and Oversight
Funding for FDA
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2029: Consolidated Appropriations Act for FY 2016
Biodefense Research, Development, and Procurement Issues
TransPacific Partnership
---Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
---Reimbursement Transparency
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Value-based contracting and communications
Drug Evaluation and Review
---Compassionate Use/Expanded Access
---FDA Proposed Rule on Changes to Drug Labeling
---Implementation of the FDA Safety and Innovation Act
---Reauthorization of the Prescription Drug User Fee Act
---Special Medical Use/Limited Population Drug
Orphan Drug Act Tax Credit
Senate Innovation for Healthier Americans
---Biomarkers and Regulatory Science Improvements
---Communication with Healthcare Professionals and Payors
---Expanded Access to Investigational Drugs
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---Innovation Incentives
---Longitudinal Study of Chronic Diseases
---Patient Access to Approved Drugs
---Patient-Focused Drug Development
---Use of Real-World Evidence
---Vaccine and Anti-Microbial Resistance Product Development and Incentives
---Generic Entry Incentives
Vaccines and Infectious Diseases - General
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.2029: Consolidated Appropriations Act for FY 2016
Government Price Reporting
---H.R.2029: Consolidated Appropriations Act for FY 2016
Gene Editing Technologies
---H.R. 2029: Consolidated Appropriations Act for 2016
Antibiotic & Diagnostic Tax Credit
---H.R. 3539: Antibiotic & Diagnostic Innovation Act
Precision Medicine Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), U.S. Trade Representative (USTR), Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Anna |
Weinstein |
|
|
|
Cartier |
Esham |
|
|
|
Catharine |
Harris |
|
|
|
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Jamie |
Gregorian |
|
|
|
Joseph |
Damond |
|
|
|
Kathleen |
Holcombe |
|
|
|
Kelly |
Cappio |
|
|
|
Laurel |
Todd |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tracey |
LaTurner |
|
|
|
Tom |
DiLenge |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development, and Procurement Issues (Non-funding)
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Jamie |
Gregorian |
|
|
|
Kelly |
Cappio |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Funding for National Institutes of Health
---H.R.2029: Consolidated Appropriations Act for FY 2016
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---H.R.2029: Consolidated Appropriations Act for FY 2016
Biodefense Research, Development, and Procurement Issues (Non-funding)
Senate Innovation for Healthier Americans Initiative
---Longitudinal Study of Chronic Diseases
Funding for Combating Antibiotic-Resistant Bacteria (CARB) Initiative
---H.R.2029: Consolidated Appropriations Act for FY 2016
Gene Editing Technologies
---H.R. 2029: Consolidated Appropriations Act for 2016
Precision Medicine Initiative
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Walker |
|
|
|
Jamie |
Gregorian |
|
|
|
Kathleen |
Holcombe |
|
|
|
Kelly |
Cappio |
|
|
|
Nicolas |
Magallanes |
|
|
|
Phyllis |
Arthur |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Cartier |
Esham |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicaid Pricing and Rebates
---Implementation of Affordable Care Act
---Average Manufacturer Price Calculations
Reimbursement for Innovative Products
---Medicare Part B Physician-Administered Products
---Medicare Part D Prescription Drug Program
---Value-Based Contracting and Communications
Senate Innovation for Healthier Americans Initiative
---Patient Access to Approved Drugs
Government Price Reporting
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Catharine |
Harris |
|
|
|
Erin |
Estey Hertzog |
|
|
|
Jamie |
Gregorian |
|
|
|
Kathleen |
Holcombe |
|
|
|
Laurel |
Todd |
|
|
|
Nicolas |
Magallanes |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Tracey |
LaTurner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Sarbanes Oxley Section 404 (b)
---H.R. 4139: the Fostering Innovation Act
Capital Formation Investment Incentives
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 341: Start-up Jobs and Innovation Act
---S. 537: COMPETE Act
---H.R. 2179: PARTNER Act
Reform of SEC Regulation D
---S. 978: the HALOS Act
Expansion of Exemption under SEC Regulation A
---H.R. 1839: Reforming Access for Investments in Startup Enterprises (RAISE) Act
Legislative Amendments to SEC Rule 12b-2 Filing Status Definitions
XBRL Exemption for Small Public Companies
---H.R. 5405: Promoting Job Creation and Reducing Small Business Burdens Act
---H.R. 1965: Small Company Disclosure Simplification Act
Capital Market Enhancements
---H.R. 1525: Disclosure Modernization and Simplification Act
---H.R. 1723: Small Company Simple Registration Act
---H.R. 2064: Improving Access to Capital for Emerging Growth Companies Act
---H.R. 4168: Small Business Capital Formation Enhancement Act
---H.R. 3784: Securities & Exchange Commission Small Business Advocate Act
-- H.R. 2357: Accelerating Access to Capital Act
Proxy Advisory Services
---Impact of Policies on Small Public Companies
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Renewable Chemicals/Bio-based Products
---S. 1267/H.R. 3084: Renewable Chemical Production Tax Credit Act
Biofuels (Non-Funding)
---Accelerated Depreciation Extension
---Production Tax Credit Extension
---H.R.2029: Consolidated Appropriations Act for FY 2016
------Protecting Americans from Tax Hikes (PATH) Act of 2015
Research & Development Tax Credit Reforms
---Extension
---Permanency
---Refundable R&D Credit
---H.R.880: To amend the Internal Revenue Code to make permanent the credit for increasing research activities
---S. 537: COMPETE Act
---S. 341: Start-up Jobs and Innovation Act
---H.R.2029: Consolidated Appropriations Act for FY 2016
------Protecting Americans from Tax Hikes (PATH) Act of 2015
Antibiotic & Diagnostic Tax Credit
---H.R. 3539: Antibiotic & Diagnostic Innovation Act
Capital Formation Investment Incentives
---Reform of Capital Gains Rules
---Reform of Net Operating Loss Rules
---Reform of Passive Loss Rules
---S. 537: COMPETE Act
---S. 341: Start-up Jobs and Innovation Act
---H.R. 2179: PARTNER Act
Tax Reform
---Innovation Box/Patent Box
Orphan Drug Act Tax Credit
Controlled Foreign Corporation Look-Through Rule Extension
---H.R.2029: Consolidated Appropriations Act for FY 2016
------Protecting Americans from Tax Hikes (PATH) Act of 2015
Inversions
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Crain |
|
|
|
Charles |
Fritts |
|
|
|
Erick |
Lutt |
|
|
|
Rina |
Singh |
|
|
|
Shelly |
Mui-Lipnik |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Kelly |
Cappio |
|
|
|
Tom |
DiLenge |
|
|
|
Cartier |
Esham |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Drug Importation
---H.R.2029: Consolidated Appropriations Act for FY 2016
---Amendment to HR: 3762: The Restoring Americans Healthcare Freedom Reconciliation Act of 2015
Intellectual Property International Enforcement
Foreign Agricultural Biotechnology Laws and Regulations
---Korea Biotechnology Regulations
---Asynchrony of International Approvals
---EU Ag Biotech Policies and Regulations
---China Biotechnology Regulations
Biosimilars
---Mexico Biologics Regulations
---Colombia Biologics Regulations
TransPacific Partnership
---Sanitary and Phytosanitary Issues
---Data and Intellectual Property Protections for Pharmaceuticals
Transatlantic Trade and Investment Partnership
---Intellectual Property Issues
---Reimbursement Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Charles |
Fritts |
|
|
|
Jamie |
Gregorian |
|
|
|
Joseph |
Damond |
|
|
|
Kathleen |
Holcombe |
|
|
|
Matthew |
OMara |
|
|
|
Nicolas |
Magallanes |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
|
Anna |
Weinstein |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
Synthetic Biology Issue
---H.R. 591: Engineering Biology Research and Development Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Dana |
OBrien |
|
|
|
Jeanne |
Haggerty |
|
|
|
Rina |
Singh |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Livestock Cloning/Product Labeling
---Discussions with EU on Animal Cloning
Genetically Engineered (GE) Animals
---FDA Approval
---Labeling
---One Health Legislation
---H.R.2029: Consolidated Appropriations Act for FY 2016
------Amendment to Restrict FDA Approval of GE Salmon
------Amendment on GE Salmon Labeling
Review and Labeling of Food Derived From Biotechnology
---U.S. Government Policy
---H.R. 1599: Safe and Accurate Food Labeling Act of 2015
---H.R.2029: Consolidated Appropriations Act for FY 2016
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Office of the Vice President of the United States, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brian |
Baenig (House and Senate Only) |
|
|
|
Dana |
OBrien |
|
|
|
Matthew |
OMara |
|
|
|
Tracey |
LaTurner |
|
|
|
Jeanne |
Haggerty |
|
|
|
Tom |
DiLenge |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |